Latest Intelligence on Biotech in United States

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Gilead Sciences: fierce competition awaits elvitegravir upon approval

Gilead's elvitegravir has met its primary efficacy endpoint (non-inferiority in treatment-experienced patients) in the first head-to-head trial against the already marketed integrase inhibitor Isentress. If approved, standalone elvitegravir will face fierce competition from established therapies in this patient population.

Published By Datamonitor
24 Mar 2011
Expert View
Expert View

AAN 2011: promising new Parkinson's treatment options may reduce motor fluctuations

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Developments in late-stage pipeline agents for Parkinson's disease were a key talking point at AAN 2011. Below are the highlights of the conference's coverage of new Parkinson's drugs.

Published By Datamonitor
03 May 2011
Expert View
Expert View

AAN 2011: Gilenya raises the bar for prospective MS market entrants

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. For another year running, developments in multiple sclerosis (MS) treatment research dominated proceedings. Below are the highlights of the conference's coverage of new multiple sclerosis drugs.

Published By Datamonitor
03 May 2011
Expert View
Expert View

Teva/Cephalon: acquisition bolsters branded portfolio

On May 2, 2011, Teva announced that it was to acquire US-based Cephalon for $6.8bn. The consolidation of Cephalon will accelerate Teva's strategy of an increased presence in the branded pharmaceutical market. Given that Cephalon's pipeline is heavily focused on oncology, an area in which Teva has no major branded presence, the deal will also prompt future therapeutic diversification.

Published By Datamonitor
18 May 2011
CommentWire
CommentWire

Amgen: positive pivotal data for Xgeva but cost may limit uptake

Phase III data show that treatment with Xgeva improved bone metastasis-free survival for advanced castrate-resistant prostate cancer patients, and the drug could now become the first therapy approved to delay the onset of metastasis. This would boost sales of Xgeva, but uptake may be restricted due to the high cost of treatment.

Published By Datamonitor
20 May 2011
Expert View
Expert View

APS 2011: fulranumab fails to live up to NGF hype in back pain

Datamonitor recently attended the 30th Annual Scientific Meeting of the American Pain Society in Austin, Texas, held over May 19-21, 2011. Below are the highlights of the conference's coverage of anti-NGF antibodies in chronic pain.

Published By Datamonitor
03 Jun 2011
CommentWire
CommentWire

Merck Serono: cladribine's failure is a big setback for the company, not MS patients

Swiss drugmaker Merck Serono has announced the discontinuation of additional trials for cladribine and the withdrawal of the product from the Russian and Australian markets, showing that the firm has decided to cut its losses and accept a costly failure. The decision to discontinue a once potentially blockbusting therapy is a huge setback for Merck and its multiple sclerosis portfolio.

Published By Datamonitor
22 Jun 2011
Expert View
Expert View

Bydureon successful at FDA-mandated trial, but market uptake could prove tougher challenge

Pipeline antidiabetic drug Bydureon has overcome another obstacle to approval, with developers Amylin, Eli Lilly, and Alkermes announcing that supratherapeutic doses of the product do not cause a change in heart rhythm by affecting the QT interval. These results pave the way for the resubmission of Bydureon in the US later in 2011.

Published By Datamonitor
12 Jul 2011
CommentWire
CommentWire

Bristol-Myers Squibb: positive news for rheumatoid arthritis biologic brand Orencia

Bristol-Myers Squibb has announced that the FDA has approved the subcutaneous formulation of its marketed intravenous biologic therapy Orencia. Based on primary research, Datamonitor anticipates a high degree of patient shifting from intravenous Orencia to the subcutaneous formulation and forecasts sales of the latter to reach $695m by 2019 in the US.

Published By Datamonitor
01 Aug 2011
Expert View
Expert View

"The pill" goes natural with potential new bestseller

Teva has announced the EU approval of NOMAC/E2, the first monophasic contraceptive with natural estrogen. The perceived increased safety of natural estrogen and a global launch will drive sales of the product, making it a leading hormonal contraceptive brand. To maximize its potential, however, Teva needs to show improved safety over synthetic estrogen contraceptives in post-marketing studies.

Published By Datamonitor
03 Aug 2011

« | 1 | 2 | 3 | » »|

No help is available.